In this regard, the inhibition of Epidermal Growth Factor Receptor (EGF-R) per se has not provided clinically useful results (Mehner et al., 2017), an observation suggesting that a better understanding of the biological network maintaining tumor cell survival involving Receptor Tyrosine Kinases (RTKs) might unravel new targets for modulation of chemotherapy efficacy. Here, EGFR is linked to neoplasm.